argenx (NASDAQ:ARGX) Upgraded to “Outperform” at Robert W. Baird

Robert W. Baird upgraded shares of argenx (NASDAQ:ARGX – Get Rating) from a neutral rating to an outperform rating in a research note published on Tuesday morning, The Fly reports. They currently have $460.00 price target on the stock.

Several other brokerages have also weighed in on ARGX. SVB Leerink lifted their target price on shares of argenx from $430.00 to $435.00 and gave the company an outperform rating in a research report on Friday, March 3rd. JPMorgan Chase & Co. boosted their price target on shares of argenx from €470.00 ($505.38) to €480.00 ($516.13) and gave the company an overweight rating in a research report on Monday, November 14th. Piper Sandler boosted their price target on shares of argenx from $465.00 to $475.00 and gave the company an overweight rating in a research report on Thursday, February 23rd. HC Wainwright restated a buy rating and issued a $480.00 price target on shares of argenx in a research report on Friday, March 3rd. Finally, Stifel Nicolaus boosted their price target on shares of argenx from $471.00 to $478.00 and gave the company a buy rating in a research report on Thursday, December 22nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, argenx currently has an average rating of Moderate Buy and a consensus target price of $454.50.

argenx Stock Performance

NASDAQ:ARGX opened at $357.98 on Tuesday. The firm’s 50-day moving average is $372.87 and its 200-day moving average is $373.25. argenx has a 52-week low of $267.35 and a 52-week high of $407.93. The company has a market cap of $19.86 billion, a price-to-earnings ratio of -27.26 and a beta of 0.74.

argenx (NASDAQ:ARGX – Get Rating) last issued its earnings results on Thursday, March 2nd. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($3.08) by $2.38. argenx had a negative net margin of 159.36% and a negative return on equity of 71.67%. The business had revenue of $182.12 million for the quarter, compared to analyst estimates of $177.11 million. Equities analysts predict that argenx will post -9.26 EPS for the current year.

Institutional Investors Weigh In On argenx

A number of institutional investors and hedge funds have recently modified their holdings of ARGX. Parkside Financial Bank & Trust raised its stake in shares of argenx by 144.8% during the third quarter. Parkside Financial Bank & Trust now owns 71 shares of the company’s stock worth $25,000 after buying an additional 42 shares during the last quarter. KB Financial Partners LLC raised its stake in shares of argenx by 112.5% during the first quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after buying an additional 45 shares during the last quarter. CI Investments Inc. raised its stake in shares of argenx by 202.6% during the fourth quarter. CI Investments Inc. now owns 79 shares of the company’s stock worth $30,000 after buying an additional 156 shares during the last quarter. Guardian Wealth Advisors LLC bought a new stake in shares of argenx during the third quarter worth approximately $31,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of argenx during the fourth quarter worth approximately $37,000. 57.29% of the stock is owned by institutional investors.

About argenx

(Get Rating)

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.